NCT07340853 2026-03-10
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
Clinical Trials
11 trialsNCT07458659 2026-03-09
CART-BCMA
Chulalongkorn University
Phase EARLY_PHASE1 Not yet recruiting
NCT07051850 2025-07-15
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Seoul St. Mary's Hospital
Recruiting
NCT03448978 2024-07-01
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Cartesian Therapeutics
Phase 1 Terminated
NCT06429150 2024-06-10
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT05521802 2023-03-24
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Shanghai AbelZeta Ltd.
Phase 1/2 Recruiting
NCT04097301 2022-01-19
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
AGC Biologics S.p.A.
Phase 1/2 Terminated
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT01239368 2019-12-10
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03271632 2019-09-19
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT01886976 2016-01-28
CART-138
Chinese PLA General Hospital
Phase 1/2 Unknown